For US journalists only. For non-US journalists, please click here.



Novartis gains FDA approval for Afinitor® in advanced breast cancer marking a significant milestone for women battling this disease

- *Approval represents the first major advance for US patients with advanced HR+ breast cancer since aromatase inhibitors were introduced more than 15 years ago*[1]
- *In a Phase III trial, Afinitor plus exemestane more than doubled the time women lived before the cancer worsened compared to exemestane alone*[2]
- *Afinitor, the first mTOR inhibitor approved for advanced HR+ breast cancer, is given after the disease progresses following prior therapy with letrozole or anastrozole*[2]

East Hanover, N.J., July 20, 2012 – The US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-

Media Contacts

Julie Masow
Novartis Corporation
+1 212 830 2465 (direct)
+1 862 579 8456 (mobile)
julie.masow@novartis.com

Gloria Vanderham
Novartis Oncology
+1 862 778 4268 (direct)
+1 862 926 8420 (mobile)
gloria.vanderham@novartis.com

Additional Resources

Novartis Newsmarket
Novartis Oncology
Novartis

Broadcast Quality Video

Download Afinitor B-roll Footage